Q-omics provides the consensus-scored ZNF19 profile across patient tissues and cancer cell-line models. ZNF19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF19 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, ZNF19 RNA expression shows 20,175 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LUSC, and THYM as cancer lineages where ZNF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF19 survival associations across molecular data types. ZNF19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF19 RNA expression–survival associations across cancer types. High ZNF19 expression shows favorable associations in MESO, UCEC, KIRC, KIRP, BRCA and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF19 RNA expression.
This table summarizes ZNF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF19 shows lower tumor expression in LUSC, KICH and THCA and higher tumor expression in KIRP, LIHC and CHOL. The LUSC box plot shows higher ZNF19 RNA expression in normal versus tumor tissue (log2 FC = −0.655, t-test p < 0.001).
This table shows molecular features associated with ZNF19 in patient tissues and cancer cell lines. In patient samples, ZNF19 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
